![Erin Lavelle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erin Lavelle
Direktor/Vorstandsmitglied bei
JADE BIOSCIENCES, INC.
Vermögen: - $ am 31.05.2026
Profil
Erin M.
Lavelle is currently an Independent Director at Avalyn Pharma, Inc. since 2024, an Independent Director at Jade Biosciences, Inc. starting in 2025, and a Director at Jade Biosciences, Inc. (United States) since 2024.
Former roles include Director at Vitaeris, Inc., Independent Director at Neoleukin Therapeutics, Inc., General Manager at Amgen, Inc. from 2017 to 2018, Chief Operating Officer at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2020, and Executive VP, Chief Operating & Financial Officer at Climb Bio, Inc. from 2020 to 2023.
Education includes an undergraduate degree from Yale University conferred in 1998.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AVALYN PHARMA INC -.--% | 30.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Erin Lavelle
| Unternehmen | Position | Beginn |
|---|---|---|
| JADE BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 28.04.2025 |
| AVALYN PHARMA INC. | Direktor/Vorstandsmitglied | 01.07.2024 |
Ehemalige bekannte Positionen von Erin Lavelle
| Unternehmen | Position | Ende |
|---|---|---|
| CLIMB BIO, INC. | Finanzdirektor/CFO | 10.03.2023 |
| ALDER BIOPHARMACEUTICALS, INC. | Geschäftsführer | 01.02.2020 |
| AMGEN INC. | Corporate Officer/Principal | 01.03.2018 |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Develops new treatment options for chronic inflammatory diseases | Direktor/Vorstandsmitglied | - |
| NEUROGENE INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Erin Lavelle
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
82
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Develops new treatment options for chronic inflammatory diseases | Health Technology |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
Aerovate Therapeutics, Inc.
 Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
